The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.46 (-5.31%)
Spread: 0.10 (1.176%)
Open: 8.45
High: 8.56
Low: 8.20
Prev. Close: 8.66
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Liberation Labs secures US$ 25 million loan

1 Dec 2023 07:00

RNS Number : 2952V
Agronomics Limited
01 December 2023
 

1 December 2023

Agronomics Limited

("Agronomics" or the "Company")

Liberation Labs secures US$ 25 million loan for biomanufacturing facility

Agronomics (ANIC:LSE), a leading listed company focused on the field of cellular agriculture, is pleased to announce that the United States Department of Agriculture ("USDA") has awarded Ameris Bancorp ("Ameris Bank") a US$ 25 million "Business and Industry" loan guarantee to help the continued build and the completion of Liberation Labs Holdings Inc ("Liberation Labs")'s biomanufacturing facility in Indiana, USA.Liberation Labs is currently constructing a commercial-scale, purpose-built, precision fermentation biomanufacturing facility with a capacity of 600,000 litres and a fully dedicated downstream process. The facility is a significant step forward in addressing the critical lack of fermentation capacity facing the industry. It will allow companies to produce at the necessary commercialisation scales, the capacity required to achieve favourable unit economics. The awarded loan guarantee - made available to businesses working to spur local economic development - ensures that Liberation Labs has the necessary capital to complete the build-out of the remainder of the facility over the next year. Commercial production is expected to commence by Q1 2025.

Once completed, the facility will be purpose-built for precision fermentation products that can be delivered at an optimised cost, with increased yield production and improved efficiency for a variety of novel bio-based proteins such as precision fermentation-derived egg and dairy proteins. A 3D rendering of the sophisticated 600,000L launch facility, designed to address the acute shortage in precision fermentation capacity, can be seen here.

Agronomics has invested US$ 7.6 million into Liberation Labs since its inception, which is currently carried at £18.4 million. Subject to audit, this position accounts for approximately 10.5% of Agronomics' last published Net Asset Value (30/09/2023), including post-balance sheet date adjustments. Agronomics has an equity ownership of 37.4% on a fully diluted basis.

Mark Warner CEO and Co-founder of Liberation Labs said: -

"Award of this USDA loan guarantee is continued confirmation of the importance of adding US biomanufacturing capacity and the strength of our business plan. Our project underwent significant due diligence and risk rating, and to come out the other end with a loan guarantee is a strong reflection of the quality of our team, our vision and our ability to execute."

Jim Mellon, Executive Director of Agronomics said:-

"Liberation Labs is developing state-of-the-art purpose-built fermentation infrastructure which will transform the existing fermentation capacity and help build a future in which precision fermentation proteins reach the industrial scale needed to meet growing demand in the US and across the world. With continued progress being made and key delivery timelines on track, we look forward to the operational launch in 2025."

 

 

 

About Liberation Labs

Liberation Labs is commercializing precision fermentation with a global network of purpose-built manufacturing facilities that enable the next wave of biotechnology advancements to produce bio-based consumer products at scale. We combine modern technology with fit-for-purpose design to bring reliable and cost-effective solutions that meet customer demand across the world. More information is available at www.liberationlabs.com.

About Ameris Bancorp

Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Alabama, Florida, North Carolina and South Carolina at the end of the most recent quarter.

About Agronomics

 

Agronomics is a leading listed company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital

Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKKBPOBDDDDN
Date   Source Headline
26th Oct 20217:00 amRNSInSilico Medicine sale-Correction of sale proceeds
20th Oct 20218:00 amRNSAgronomics leads investment in California Cultured
12th Oct 20217:00 amRNSExercise of Warrants and Updated TVR
29th Sep 20217:00 amRNSAnnounces Sale of Oritain Shares
28th Sep 20217:00 amRNSNew Age Meats Announces US$ 25 million Series A
22nd Sep 20212:48 pmRNSPortfolio Company Update: Mosa Meat
20th Sep 20217:00 amRNSAgronomics leads VitroLabs Series A Funding
14th Sep 20217:00 amRNSPortfolio Company Update: Meatable
14th Sep 20217:00 amRNSPortfolio Company Update: BlueNalu
13th Sep 20218:00 amRNSSubscription in Formo’s US $50 million Fundraise
30th Jul 20215:34 pmRNSReplacement: Net Asset Valuation to 30 June 2021
30th Jul 202112:02 pmRNSNet Asset Value calculation to 31 June 2021
21st Jul 20211:15 pmRNSPortfolio Company Update: Shiok Meats Pte. Ltd
15th Jul 20217:00 amRNSWarrants to be traded on J P Jenkins
14th Jul 20217:00 amRNSTwo portfolio companies in XPRIZE semi-finals
13th Jul 20217:00 amRNSHalf Year Newsletter
25th Jun 20214:21 pmRNSPortfolio Company LIVEKINDLY Update
24th Jun 20215:03 pmRNSPortfolio Company Formo Update
24th Jun 20217:00 amRNSAnnounces the Sale of InSilico Medicine Inc Shares
28th May 202112:10 pmRNSResults of General Meeting, Issue of Equity & TVR
28th May 20217:00 amRNSAnnounces the Conversion of CellX SAFE
27th May 20217:00 amRNSBroker Option Results
25th May 20217:00 amRNSUpdate regarding Broker Option
20th May 20217:00 amRNSUpdate regarding Broker Option
13th May 20217:00 amRNSAnnounces Secondary Purchase of Shares in Meatable
12th May 20217:00 amRNSResult of Fundraising
11th May 202111:05 amRNSSecond Price Monitoring Extn
11th May 202111:00 amRNSPrice Monitoring Extension
11th May 202110:40 amRNSProposed Fundraise to raise £50 million
6th May 20212:30 pmRNSNew Consultancy Agreement with Shellbay
21st Apr 20218:30 amRNSInvestee Company Update: LegenDairy Foods
21st Apr 20217:00 amRNSNet Asset Value calculation to 31 March 2021
8th Apr 202110:47 amRNSInvestee Company Update: Solar Foods
30th Mar 20217:00 amRNSInvestee Company Update: LIVEKINDLY Fundraise
23rd Mar 20213:00 pmRNSMeatable Announces US$ 47 Million Financing
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:01 pmRNSPrice Monitoring Extension
15th Mar 202111:05 amRNSSecond Price Monitoring Extn
15th Mar 202111:00 amRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSPortfolio Company Update: LIVEKINDLY Collective
25th Feb 20217:00 amRNSAnnounces Further Investment in VitroLabs
18th Feb 20217:00 amRNSAnnounces Further Investment in Meatable
11th Feb 20217:00 amRNSInvestee Company Update: New Age Meats
3rd Feb 20217:00 amRNSResult of AGM
26th Jan 20217:00 amRNSHalf-year Report
20th Jan 20217:00 amRNSInvestee Company Update: BlueNalu Secures $60m
19th Jan 20213:33 pmRNSExercise of Warrants
18th Jan 20217:00 amRNSNet Asset Value calculation to 31 December 2020
16th Dec 20207:00 amRNSInvestment in SuperMeat
14th Dec 20207:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.